🔗 Share this article Patients Coming Off Anti-Obesity Injections Regain Pounds Four Times Faster Compared to People Using Diet and Exercise Obesity treatment often requires long-term strategies. A recent study suggests that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end conventional lifestyle plans. Findings released in a prominent health publication points out that while obese people frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit. "Individuals purchasing such medications must be informed of the risk of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb. Such speed of recovery implies a reversion to starting weight within about a year and a half. Analyzing Therapies The research, which looked at 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills. The team emphasize that individuals who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 100 grams monthly—post-intervention. Explaining the Rapid Regain Nutrition scientists suggest the mechanism of the drugs is key to understanding the amplified regain. The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness. "Artificially providing the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert. "Stopping of this hormone supplement leads to appetite is uncontrolled, making overeating much more probable." An Ongoing Issue? The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes. A number of clinicians say that, given the likelihood of relapse, the treatment should be considered long-term. This perspective is reinforced by drug manufacturers, who say that the findings "highlight the long-term character of excess weight," similar to managing conditions like high blood pressure. User Experiences People who have discontinued the medication explain a powerful return of hunger. "I experienced something that goes on and I was suddenly ravenous," recalled one woman. This difficulty is compounded if patients have not established lasting lifestyle or habit changes during therapy. Widespread Interest Recent estimates indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial. Adoption is more common among females compared to males. The middle-aged demographic shows the highest level of interest. Many access the drugs through private prescriptions rather than public health services. Finally, clinicians emphasize that while these medications are effective agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on combined behavioural support.
Obesity treatment often requires long-term strategies. A recent study suggests that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass far faster than those who end conventional lifestyle plans. Findings released in a prominent health publication points out that while obese people frequently drop a large proportion of their total mass while using the jabs, the mass is regained at an estimated rate of nearly a kilo each month once they quit. "Individuals purchasing such medications must be informed of the risk of quick rebound weight gain when the medication is stopped," stated expert Dr. Susan Jebb. Such speed of recovery implies a reversion to starting weight within about a year and a half. Analyzing Therapies The research, which looked at 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with other pills. The team emphasize that individuals who lose weight through lifestyle changes alone usually have a more gradual weight regain—approximately 100 grams monthly—post-intervention. Explaining the Rapid Regain Nutrition scientists suggest the mechanism of the drugs is key to understanding the amplified regain. The injections imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness. "Artificially providing the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its effects," explained Dr. Adam Collins, a dietetics expert. "Stopping of this hormone supplement leads to appetite is uncontrolled, making overeating much more probable." An Ongoing Issue? The NHS suggest the injections for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes. A number of clinicians say that, given the likelihood of relapse, the treatment should be considered long-term. This perspective is reinforced by drug manufacturers, who say that the findings "highlight the long-term character of excess weight," similar to managing conditions like high blood pressure. User Experiences People who have discontinued the medication explain a powerful return of hunger. "I experienced something that goes on and I was suddenly ravenous," recalled one woman. This difficulty is compounded if patients have not established lasting lifestyle or habit changes during therapy. Widespread Interest Recent estimates indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial. Adoption is more common among females compared to males. The middle-aged demographic shows the highest level of interest. Many access the drugs through private prescriptions rather than public health services. Finally, clinicians emphasize that while these medications are effective agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on combined behavioural support.